Business Wire

LINESIGHT

3.2.2021 12:59:04 CET | Business Wire | Press release

Share
Linesight Poised for Future Global Expansion With New CEO

Multinational consultancy firm, Linesight, announced today that it is promoting Paul Boylan to the position of Chief Executive Officer (CEO) and welcoming Tom Dempsey as COO.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210203005457/en/

Boylan has been appointed as the new Chief Executive Officer (CEO) and will be taking over from Gerard Campbell who will remain on the Executive Board throughout 2021. Boylan joined Linesight in 2002 and has amassed over twenty-five years of experience in the global construction industry. He has played a pivotal role in growing Linesight’s client base and expanding the company’s reach geographically.

“Gerard Campbell has made an enormous contribution to Linesight over four decades and will continue to provide valuable strategic inputs on our Executive Board in the coming year,” said Boylan “We are focused on building on the strong foundation Gerard has established, working with our highly skilled and committed global teams who are empowered and motivated to collaborate with our clients for success. Our ability to be agile and rapidly respond to market and client needs will remain a key tenet of our strategic and operational approach going forward.”

Tom Dempsey has also recently joined Linesight’s Executive Leadership team as the new Chief Operations Officer (COO). Dempsey has extensive experience in the pharmaceutical and technology sectors and has held a variety of roles, include VP Global Operations, at Hewlett Packard in the Real Estate function. “I am thrilled to be taking on the role of COO and look forward to supporting Linesight’s ambitious goals of becoming a global authority in construction project, program, scheduling and cost management,” said Dempsey “This is truly an exciting time in Linesight’s evolution as an industry innovator.”

Over the past three years Linesight has extensively expanded its client base in several key sectors, including the Data Center, Life Sciences, Commercial, High-Tech Industry and Residential sectors, in its targets regions of the Americas, Europe, APAC and the Middle East. Year on year revenue growth has been profitable at over 20% owing to the explicit and strategic evolution of the company. Linesight now has twenty-two offices worldwide and over seven hundred skilled team members. With new senior leadership in place Linesight is well structured to deliver on its ambitious growth aspirations which include geographical and team expansion to maximize value for their clients.

ENDS

About Linesight

Linesight is a multinational consultancy firm with over 45 years' experience, providing cost, schedule, program and project management services to a multitude of sectors including Life Sciences, Commercial, Data Centers, High-Tech Industrial, Residential, Hospitality, Aviation, Transport and Infrastructure, Healthcare and Retail. Linesight’s specialist project teams, each with specific skills and experience, provide faster project delivery, greater cost efficiency, predictability in project planning and maximum value for money for their clients. For further information, please visit http://www.linesight.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 07:00:00 CEST | Press release

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4 Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the

Stonebranch is Again Named a Leader in the 2026 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 17:00:00 CEST | Press release

Gartner recognizes Stonebranch as a Leader for the third consecutive year based on Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build

Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 16:09:00 CEST | Press release

New facility in Cummings Research Park brings engineering closer to customers while advancing mission processing technologies and strengthening Frontgrade's long-term investment in Huntsville Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboratio

Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release

Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye